CAR-T cell engineering with CCR6 exhibits superior anti-solid tumor efficacy

• 作者: Cheng Zhong Jun Chen
• 来源期刊: 科学通报（英文版）
• 年，卷（期）: 2021,（8）
• 所属期刊栏目: RESEARCH HIGHLIGHTS
• 页码范围: 755-756
• 页数: 2页
• 语种: 英文

摘要

Immune cell-based therapies provide promising strategies for the treatment of hematologic malignancies.CAR-T immunotherapy, referring to T cells engineered to express chimeric antigen receptors (CARs), which targeted CD19-expressing B-cell-derived tumors, has demonstrated remarkable and durable clinical responses in patients with hematological cancers [1].However, CAR-T immunotherapy has to date been comparatively less effective for solid tumors, primarily due to their limited penetration into solid tumors [2].A recent study reported that high endothelial venules (HEVs) restricts the recruitment of cytotoxic effector T lymphocytes through a physical barrier in numerous types of human tumors [3].